Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 4 | 2024 | 505 | 1.630 |
Why?
|
| Diabetic Ketoacidosis | 2 | 2019 | 9 | 1.250 |
Why?
|
| Blood Glucose | 4 | 2021 | 401 | 1.150 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2024 | 64 | 0.990 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 415 | 0.940 |
Why?
|
| Hospitalization | 2 | 2024 | 729 | 0.780 |
Why?
|
| Thrombocythemia, Essential | 1 | 2022 | 2 | 0.780 |
Why?
|
| Primary Myelofibrosis | 1 | 2022 | 10 | 0.770 |
Why?
|
| Hyperglycemia | 2 | 2020 | 92 | 0.750 |
Why?
|
| Diabetic Neuropathies | 1 | 2021 | 5 | 0.730 |
Why?
|
| Diplopia | 1 | 2021 | 6 | 0.730 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 137 | 0.690 |
Why?
|
| Gastroparesis | 1 | 2019 | 3 | 0.630 |
Why?
|
| Ketosis | 1 | 2019 | 1 | 0.630 |
Why?
|
| Colorectal Surgery | 1 | 2019 | 22 | 0.620 |
Why?
|
| Hypoparathyroidism | 1 | 2019 | 3 | 0.610 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 5 | 0.610 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 563 | 0.610 |
Why?
|
| Insulin | 2 | 2021 | 616 | 0.600 |
Why?
|
| Metformin | 1 | 2019 | 45 | 0.590 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 63 | 0.590 |
Why?
|
| Autoantibodies | 1 | 2019 | 125 | 0.590 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 173 | 0.550 |
Why?
|
| Aged | 8 | 2024 | 8182 | 0.440 |
Why?
|
| Argyria | 1 | 2013 | 1 | 0.420 |
Why?
|
| Silver Compounds | 1 | 2013 | 1 | 0.420 |
Why?
|
| Sella Turcica | 1 | 2013 | 1 | 0.410 |
Why?
|
| Pituitary Neoplasms | 1 | 2013 | 16 | 0.410 |
Why?
|
| Dacarbazine | 1 | 2013 | 12 | 0.410 |
Why?
|
| Complementary Therapies | 1 | 2013 | 24 | 0.410 |
Why?
|
| Sarcoma | 1 | 2013 | 28 | 0.400 |
Why?
|
| Humans | 15 | 2024 | 40217 | 0.390 |
Why?
|
| Retrospective Studies | 5 | 2024 | 3138 | 0.370 |
Why?
|
| Glucagon | 1 | 2011 | 30 | 0.350 |
Why?
|
| Pheochromocytoma | 1 | 2011 | 19 | 0.350 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2011 | 34 | 0.350 |
Why?
|
| Agranulocytosis | 1 | 2010 | 4 | 0.340 |
Why?
|
| Methimazole | 1 | 2010 | 7 | 0.340 |
Why?
|
| Thyroid Crisis | 1 | 2010 | 4 | 0.340 |
Why?
|
| Plasmapheresis | 1 | 2010 | 10 | 0.340 |
Why?
|
| Antithyroid Agents | 1 | 2010 | 17 | 0.330 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 326 | 0.330 |
Why?
|
| Hypoglycemic Agents | 2 | 2021 | 143 | 0.290 |
Why?
|
| Male | 8 | 2024 | 18271 | 0.260 |
Why?
|
| Female | 7 | 2024 | 20392 | 0.230 |
Why?
|
| Middle Aged | 5 | 2024 | 10090 | 0.220 |
Why?
|
| Hydroxyurea | 1 | 2022 | 16 | 0.190 |
Why?
|
| Prognosis | 2 | 2022 | 921 | 0.190 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2021 | 49 | 0.170 |
Why?
|
| Cohort Studies | 1 | 2024 | 1479 | 0.170 |
Why?
|
| Glucocorticoids | 1 | 2020 | 93 | 0.160 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2019 | 2 | 0.160 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2019 | 1 | 0.150 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 4 | 0.150 |
Why?
|
| Intensive Care Units | 1 | 2021 | 215 | 0.150 |
Why?
|
| Coronary Angiography | 1 | 2019 | 87 | 0.150 |
Why?
|
| Critical Illness | 1 | 2021 | 179 | 0.150 |
Why?
|
| Hypocalcemia | 1 | 2019 | 15 | 0.150 |
Why?
|
| Insulin Infusion Systems | 1 | 2018 | 10 | 0.150 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 47 | 0.150 |
Why?
|
| Income | 1 | 2019 | 124 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2021 | 680 | 0.150 |
Why?
|
| Contrast Media | 1 | 2019 | 208 | 0.140 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 252 | 0.130 |
Why?
|
| Thyroidectomy | 2 | 2019 | 15 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2020 | 1165 | 0.120 |
Why?
|
| Algorithms | 1 | 2018 | 673 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2018 | 591 | 0.100 |
Why?
|
| Adult | 2 | 2021 | 10255 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 520 | 0.090 |
Why?
|
| Gastrointestinal Motility | 1 | 2011 | 4 | 0.090 |
Why?
|
| Gastrointestinal Agents | 1 | 2011 | 9 | 0.090 |
Why?
|
| Colonoscopy | 1 | 2011 | 67 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 3136 | 0.080 |
Why?
|
| Thyrotoxicosis | 1 | 2010 | 5 | 0.080 |
Why?
|
| Graves Disease | 1 | 2010 | 14 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2010 | 2863 | 0.050 |
Why?
|
| Immunocompetence | 1 | 2003 | 17 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2003 | 200 | 0.050 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2003 | 170 | 0.050 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2003 | 182 | 0.050 |
Why?
|
| Islets of Langerhans | 1 | 2003 | 265 | 0.040 |
Why?
|
| United States | 2 | 2020 | 4886 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 47 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 137 | 0.040 |
Why?
|
| Thyroid Gland | 1 | 2019 | 70 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 257 | 0.040 |
Why?
|
| Incidence | 1 | 2020 | 773 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 585 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 1367 | 0.030 |
Why?
|
| Risk Factors | 1 | 2020 | 3141 | 0.030 |
Why?
|
| Glucuronic Acid | 1 | 2003 | 14 | 0.010 |
Why?
|
| Hexuronic Acids | 1 | 2003 | 17 | 0.010 |
Why?
|
| Capsules | 1 | 2003 | 34 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2003 | 156 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2003 | 89 | 0.010 |
Why?
|
| Alginates | 1 | 2003 | 41 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2003 | 183 | 0.010 |
Why?
|
| Cellular Senescence | 1 | 2003 | 88 | 0.010 |
Why?
|
| Swine | 1 | 2003 | 229 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 387 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 456 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2003 | 368 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2003 | 1116 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 2422 | 0.010 |
Why?
|
| Mice | 1 | 2003 | 8809 | 0.010 |
Why?
|
| Animals | 1 | 2003 | 16893 | 0.000 |
Why?
|